Jenny Rowe
Charles River Laboratories (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Cancer Immunotherapy and Biomarkers, Cancer Research and Treatments, Acute Myeloid Leukemia Research
Most-Cited Works
- → Genetic Analysis of Varicella-Zoster Virus ORF0 to ORF4 by Use of a Novel Luciferase Bacterial Artificial Chromosome System(2007)96 cited
- → Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia(2021)33 cited
- → Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice(2010)30 cited
- → Humanized NOG mice as a model for tuberculosis vaccine‐induced immunity: a comparative analysis with the mouse and guinea pig models of tuberculosis(2017)20 cited
- → Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML(2022)9 cited
- → SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model(2023)4 cited
- → Non-Clinical Cell Therapy Development Using the NCG Mouse Model as a Test System(2023)4 cited
- → 247 Assessment of sensitivity to a PD-1 check point inhibitor and cisplatin in bladder cancer patient-derived xenografts with various levels of PD-L1 expression in HuCD34NCG mice(2020)3 cited
- → 199 Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34+ stem cell humanized NCG (HuCD34NCG) mouse model(2020)2 cited
- → Abstract 5625: Evaluation of in vivo anti-tumor response of solid tumors in a novel immune cell-humanized NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl mouse model(2020)2 cited